肝胆相照论坛

标题: 箭头新消息 [打印本页]

作者: 齐欢畅    时间: 2019-9-3 20:21     标题: 箭头新消息

本帖最后由 齐欢畅 于 2019-9-3 22:36 编辑

箭头新消息无法转载
作者: 齐欢畅    时间: 2019-9-3 22:32

Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences
Aug 30, 2019 at 4:00 PM EDT
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Baird's 2019 Global Healthcare Conference – New York , September 4-5, 2019 September 4 , 9:40 a.m.
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Aug. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Baird's 2019 Global Healthcare Conference – New York, September 4-5, 2019

September 4, 9:40 a.m. EDT –Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will deliver a corporate presentation

Citi’s 14th Annual Biotech Conference– Boston, September 5, 2019

Global Summit on Cardiology and Heart Diseases – Dubai, UAE, September 16-17, 2019

September 16, 11:00 a.m. GST –Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, “Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases”

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.



View source version on businesswire.com: https://www.businesswire.com/news/home/20190830005380/en/

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]
www.lifesciadvisors.com
作者: 齐欢畅    时间: 2019-9-3 22:33

箭头药品参加即将到来的2019年9月会议
2019年8月30日美国东部时间下午4点
加州帕萨迪纳市——(业务线)——8月。 2019——箭头制药有限公司(纳斯达克:ARWR)今天宣布,它将参与以下即将来临的事件:Baird的2019年全球医疗会议——纽约,4 - 9月,2019年9月4日上午9:40之间。
PDF版本
加州帕萨迪纳市——(业务线)——8月。 2019——箭头制药有限公司(纳斯达克:ARWR)今天宣布,它将参加即将来临的事件如下:

Baird的2019年全球医疗会议——纽约,2019年9月4 - 5日

Anzalone屁股的40点。美国东部时间9月4日,博士,箭头的总裁兼首席执行官,将企业介绍

花旗的14日生物技术年会——波士顿,2019年9月5日

全球峰会在心脏病和心脏疾病——迪拜,阿联酋,2019年9月16 - 17日

9月16日上午11:00 GST -布鲁斯,医学博士 箭头的首席运营官,主管研发,将主旨演讲题为“用RNA干扰治疗hypertriglyceridemic州——出现一个令人兴奋的新方法来治疗心血管疾病”

报告的一个副本材料和网络直播链接,如果表示网络直播,可能会在事件和演示页面访问的投资者部分箭头的网站。

关于箭头制药

箭头制药发展药物治疗棘手的疾病通过沉默的基因使他们。 使用广泛的RNA组合化学和高效的方式交付,箭头治疗触发RNA干扰机制诱导迅速,深,耐用击倒目标基因。 RNA干扰、RNAi是一种机制存在于活细胞,抑制特定基因的表达,从而影响生产的一个特定的蛋白质。 箭头的RNAi-based疗法利用该基因沉默的自然途径。

有关更多信息,请访问www.arrowheadpharma.com,或者在Twitter上关注我们@ArrowheadPharma。 添加到该公司的电子邮件列表和直接接收的消息,请访问http://ir.arrowheadpharma.com/email-alerts

安全港声明下私人证券诉讼改革法案:

本新闻稿中包含前瞻性陈述的意义在“安全港”规定私人证券诉讼改革法案1995。 这些报表是基于我们当前的预期,只讲的日期。 实际结果可能不同物质和负面的表达在任何前瞻性陈述由于各种因素和不确定性,包括我们产品的安全性和有效性的候选人,监管延迟的时间和影响我们的临床程序,我们财务业务的能力,未来的里程碑的可能性和时间的收据和许可费用,未来我们科学研究的成功,我们成功地开发和商业化候选药物的能力,开始的时间和完成临床试验,快速的技术变化在我们的市场,我们的知识产权执法。 我们最近的年度报告形式10 - 10 - k和随后的季度报告形式讨论一些重要的危险因素,可能会影响我们的业务,业务和财务状况的结果。 我们假设没有义务更新或修订前瞻性陈述,以反映新的事件或环境。

来源:箭头制药公司。



查看源代码版本在businesswire.com上:https://www.businesswire.com/news/home/20190830005380/en/

来源:箭头制药公司。

箭头制药有限公司
文斯Anzalone, CFA
626-304-3400
[email protected]

投资者和媒体:
LifeSci Advisors LLC
布莱恩•里奇
作者: 齐欢畅    时间: 2019-9-3 22:33

Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Aug 28, 2019 at 7:30 AM EDT
- Arrowhead earns $25 million milestone payment in connection with trial initiation PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson &
PDF Version
- Arrowhead earns $25 million milestone payment in connection with trial initiation

PASADENA, Calif.--(BUSINESS WIRE)--Aug. 28, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has begun dosing in a Phase 2b study (REEF-1) of different combination regimens, including JNJ-3989 (formerly ARO-HBV), and/or JNJ-6379, and a nucleos(t)ide analog (NA) for the treatment of chronic hepatitis B virus infection. In connection with the start of this study, Arrowhead earned a $25 million milestone payment from Janssen.

JNJ-3989 is a liver-targeted investigational antiviral therapeutic for subcutaneous injection designed to treat chronic HBV infection via the ribonucleic acid interference (RNAi) mechanism. JNJ-6379 is an investigational orally administered capsid assembly modulator of the class that forms normal capsid structures (CAM-N). Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV.

Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: “Patients with chronic hepatitis B infection are in need of new medicines that improve functional cure rates with finite treatment regimens. We are thrilled that JNJ-3989, formerly ARO-HBV, is one of the agents being investigated in Janssen’s REEF-1 triple combination Phase 2b study.”

REEF-1 (NCT03982186) is a Phase 2b, multicenter, double-blind, active-controlled, randomized study to investigate the efficacy and safety of different combination regimens, including JNJ-3989, JNJ-6379, NA, and/or placebo in patients with chronic hepatitis B virus infection. The study is planned to include up to 450 patients who will be randomized to receive up to 48 weeks of treatment.

Hepatitis B infection is a life-threatening viral infection of the liver, which can cause cirrhosis — scarring of liver tissue — and liver cancer after prolonged period of chronic infection. The World Health Organization cites that hepatitis B is a global public health problem affecting 292 million people worldwide.1 While a preventive vaccine is available, cure rates for those infected remain low and most patients will endure lifelong therapy.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

1 The Polaris Observatory Conservatory. Global prevalence, treatment, and prevention of hepatitis B. The Lancet Gastroenterology & Hepatology. VOLUME 3, ISSUE 6, P383-403, JUNE 01, 2018



View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005119/en/

Source: Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
[email protected]

Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
[email protected]
www.lifesciadvisors.com
作者: newchinabok    时间: 2019-9-3 23:25

本帖最后由 newchinabok 于 2019-9-3 23:27 编辑

前几天都有了




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5